S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
Major Financial Crisis Could Hit America (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
Major Financial Crisis Could Hit America (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
Major Financial Crisis Could Hit America (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
Major Financial Crisis Could Hit America (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
NASDAQ:INAB

IN8bio (INAB) Stock Forecast, Price & News

$2.73
-0.42 (-13.33%)
(As of 06/5/2023 ET)
Compare
Today's Range
$2.56
$3.05
50-Day Range
$1.05
$3.24
52-Week Range
$1.02
$3.95
Volume
702,551 shs
Average Volume
2.26 million shs
Market Capitalization
$81.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.33

IN8bio MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
205.3% Upside
$8.33 Price Target
Short Interest
Healthy
1.14% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.67mentions of IN8bio in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.10) to ($1.16) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

685th out of 986 stocks

Biological Products, Except Diagnostic Industry

110th out of 165 stocks


INAB stock logo

About IN8bio (NASDAQ:INAB) Stock

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Receive INAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IN8bio and its competitors with MarketBeat's FREE daily newsletter.

INAB Stock News Headlines

The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
IN8bio (INAB) Gets a Buy from EF Hutton
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Recap: IN8bio Q1 Earnings
Why Is IN8bio (INAB) Stock Up 9% Today?
H.C. Wainwright Keeps Their Buy Rating on IN8bio (INAB)
Short Volatility Alert: In8bio Inc
IN8bio Soars after Promising Drug Data
See More Headlines

INAB Price History

INAB Company Calendar

Last Earnings
3/30/2023
Today
6/05/2023
Next Earnings (Estimated)
8/11/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INAB
Fax
N/A
Employees
19
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.33
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+205.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-28,520,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.93 per share

Miscellaneous

Free Float
19,100,000
Market Cap
$81.22 million
Optionable
Not Optionable
Beta
0.29

Key Executives

  • Mr. Tai-Wei Ho (Age 47)
    Co-Founder, Pres, CEO & Director
    Comp: $727.46k
  • Dr. Lawrence S. Lamb Ph.D. (Age 69)
    Exec. VP, Co-Founder & Chief Scientific Officer
    Comp: $482.47k
  • Mr. Patrick McCall CPA (Age 40)
    CFO & Sec.
    Comp: $519.35k
  • Dr. Kate Rochlin Ph.D. (Age 42)
    Chief Operating Officer
  • Dr. Trishna Goswami M.D.
    Chief Medical Officer
  • Dr. Kenneth R. LaMontagne Ph.D.
    Sr. VP of Bus. Devel.













INAB Stock - Frequently Asked Questions

Should I buy or sell IN8bio stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IN8bio in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" INAB shares.
View INAB analyst ratings
or view top-rated stocks.

What is IN8bio's stock price forecast for 2023?

3 Wall Street analysts have issued 1-year price objectives for IN8bio's shares. Their INAB share price forecasts range from $3.00 to $14.00. On average, they predict the company's stock price to reach $8.33 in the next year. This suggests a possible upside of 205.3% from the stock's current price.
View analysts price targets for INAB
or view top-rated stocks among Wall Street analysts.

How have INAB shares performed in 2023?

IN8bio's stock was trading at $2.31 at the start of the year. Since then, INAB stock has increased by 18.2% and is now trading at $2.73.
View the best growth stocks for 2023 here
.

Are investors shorting IN8bio?

IN8bio saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 137,500 shares, a drop of 88.4% from the April 30th total of 1,190,000 shares. Based on an average trading volume of 3,630,000 shares, the short-interest ratio is presently 0.0 days. Currently, 1.1% of the company's shares are sold short.
View IN8bio's Short Interest
.

When is IN8bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our INAB earnings forecast
.

How were IN8bio's earnings last quarter?

IN8bio, Inc. (NASDAQ:INAB) announced its quarterly earnings data on Thursday, March, 30th. The company reported ($0.32) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by $0.04.

When did IN8bio IPO?

(INAB) raised $44 million in an initial public offering on Friday, July 30th 2021. The company issued 4,000,000 shares at $10.00-$12.00 per share. B. Riley Securities acted as the underwriter for the IPO.

What is IN8bio's stock symbol?

IN8bio trades on the NASDAQ under the ticker symbol "INAB."

Who are IN8bio's major shareholders?

IN8bio's stock is owned by many different institutional and retail investors. Top institutional investors include Sigma Planning Corp (0.82%) and Dimensional Fund Advisors LP (0.10%). Insiders that own company stock include Emily Fairbairn, Kate Rochlin, Lawrence Lamb, Trishna Goswami and William Tai-Wei Ho.
View institutional ownership trends
.

How do I buy shares of IN8bio?

Shares of INAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IN8bio's stock price today?

One share of INAB stock can currently be purchased for approximately $2.73.

How much money does IN8bio make?

IN8bio (NASDAQ:INAB) has a market capitalization of $81.22 million. The company earns $-28,520,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis.

How can I contact IN8bio?

IN8bio's mailing address is 79 Madison Avenue, New York, New York 10016. The official website for the company is www.in8bio.com. The company can be reached via phone at 646-600-6438 or via email at dbuck@soleburytrout.com.

This page (NASDAQ:INAB) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -